Horizon Discovery Secures $383 Million in Funding for Revolutionary Gene Editing Innovations

Horizon Discovery, a pioneering force in gene editing and modulation, has successfully raised an impressive $383 million in a recent funding round, bolstering its mission to revolutionize precision medicine. Formerly part of PerkinElmer and now integrated into the Revvity family, Horizon Discovery stands at the forefront of enabling academic institutions, pharmaceutical and biotechnology companies, and clinical diagnostic laboratories to gain deeper insights into the genetic underpinnings of human diseases. With an extensive track record spanning over a decade in the engineering of cell lines, Horizon Discovery provides innovative tools and services designed to modulate or permanently alter gene functionality across human and mammalian cell lines. This substantial funding will be strategically used to further enhance Horizon's cutting-edge technologies, expand its portfolio of services, and accelerate its capability to develop diagnostic workflows that facilitate the delivery of targeted therapies. Headquartered in Cambridge, UK, with operational bases in the USA and Japan, Horizon is poised to deepen its global impact on life sciences research. The investment not only fortifies Horizon's position in the competitive landscape but also signals a growing recognition of the potential for gene modulation technologies to transform patient outcomes. As the company moves forward, it remains committed to driving innovation that empowers researchers and clinicians alike to effectively tackle the complexities of human health and disease.